Hennessy Quoted in Law360 About COVID Health Apps and Privacy Laws
September 18, 2020
Law360
Senior Counsel Jennifer Hennessy was quoted in the Law360 article, “Amid Pandemic, Health Apps Face Privacy Law Patchwork,” which discussed how in a surging market thanks to the coronavirus pandemic, developers of mobile health apps are facing challenges on how to comply with a patchwork of state data security laws.
Much of the traditional health care space is covered by the rigorous data security requirements outlined by federal regulators in the Health Insurance Portability and Accountability Act, or HIPAA. But other companies, like private businesses building apps to screen employees for symptoms of COVID-19, may not be subject to HIPAA’s requirements despite handling sensitive health data.
Separately, the current FTC in May solicited input about whether it should change a decade-old, little-used rule requiring companies that are not covered by HIPAA but still handle health information to publicly report data breaches. The commission asked for advice on whether it should change its Health Breach Notification Rule in light of “legal, economic, and technological changes,” including “developments in health care products or services related to COVID-19.”
The FTC noted at the time that more companies may soon be covered by its rule as patients increasingly turn to technologies such as virtual assistants and mobile health apps that might not be subject to HIPAA. Those companies are instead struggling to navigate a slew of differing state laws addressing how health data should be protected and how to handle a potential data breach. “We think health care and HIPAA go together in this country, and that’s true most of the time, but not always,” Hennessy said.
Much of the traditional health care space is covered by the rigorous data security requirements outlined by federal regulators in the Health Insurance Portability and Accountability Act, or HIPAA. But other companies, like private businesses building apps to screen employees for symptoms of COVID-19, may not be subject to HIPAA’s requirements despite handling sensitive health data.
Separately, the current FTC in May solicited input about whether it should change a decade-old, little-used rule requiring companies that are not covered by HIPAA but still handle health information to publicly report data breaches. The commission asked for advice on whether it should change its Health Breach Notification Rule in light of “legal, economic, and technological changes,” including “developments in health care products or services related to COVID-19.”
The FTC noted at the time that more companies may soon be covered by its rule as patients increasingly turn to technologies such as virtual assistants and mobile health apps that might not be subject to HIPAA. Those companies are instead struggling to navigate a slew of differing state laws addressing how health data should be protected and how to handle a potential data breach. “We think health care and HIPAA go together in this country, and that’s true most of the time, but not always,” Hennessy said.
People
Related News
August 13, 2025
In the News
Leigh Riley on Elevating Partner Development with Foley's PEAK Program – 'We can't stop learning'
Foley & Lardner LLP partner Leigh Riley appeared on the Big Law Life podcast to share how Foley is redefining professional development to meet the needs of the firm's partners and the demands of modern legal practice.
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."